Latest news with #argenxSE
Yahoo
15-05-2025
- Business
- Yahoo
argenx SE (ARGX): Among the Best Growth Stocks to Buy and Hold for the Long Term
We recently compiled a list of the . In this article, we are going to take a look at where argenx SE (NASDAQ:ARGX) stands against the other growth stocks. The market closed last week mostly lower, however, the S&P 500 has been up more than 7% since April 11, indicating a returning positive sentiment. On May 10, David Lefkowitz, Equity Strategist at UBS Global Wealth Management, joined CNBC to discuss his bull case for the US equities. Lefkowitz acknowledged the volatility that has been around since the tariff announcement; however, he believes that backdrop remains fairly constructive. He elaborated that the market has had some significant buy signals since early April, characterised by the volatility index giving one of the highest readings, investor sentiment being cautious, and investor positioning has been depressed. Historically speaking, whenever these things have happened in the past, the US equities have performed exceptionally well in the preceding 6 to 12 months. Lefkowitz noted that he is not too concerned with the day-to-day news and volatility, as the market will get choppy on trade negotiation deals. Rather, he is more focused on the bigger picture, which indicates that stocks will ultimately end up higher over the next 12 months. While answering a question regarding the recent rebound in the market, Lefkowitz highlighted that when the volatility index comes down, as it has over the past few weeks, history tells us that the market does not make new lows. Although the market will still be chopping a little. However, it is anticipated to stay within the historic average of 5%. Moreover, the equity strategist is also not concerned about the valuations and believes that as soon as the companies start posting earnings growth, the backdrop will help the market reach its next high. While talking about his most convicted sectors, Lefkowitz noted that he likes secular growth stocks. He elaborated that growth as a sector was hit earlier this year due to doubts regarding AI trends and its ability to generate a return on investment. This has resulted in the sector being at the bottom of the market. However, Lefkowitz believes that the demand for AI products and the sophisticated infrastructure will keep growing for at least the next few years, thereby generating sustainable earnings growth. To compile the list of 12 best growth stocks to buy and hold for the long term, we used the Finviz stock screener, Seeking Alpha, and Insider Monkey's Q4 2024 hedge fund database. Using the screener, we aggregated a list of growth stocks that have grown their sales by at least 30% over the past 5 years. Next, we cross-checked the 5-year sales growth for each stock from Seeking Alpha and ranked the stocks in ascending order of the number of hedge fund investors. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (). A lab setting filled with scientific equipment and researchers in lab coats working together to develop new therapies for autoimmune diseases. argenx SE (NASDAQ:ARGX) is a commercial-stage biotechnology company that focuses on developing antibody therapeutics for autoimmune diseases and cancer. It uses its proprietary discovery platform to leverage unique characteristics of the llama immune system and engineer antibody medicines. Its lead products, VYVGART and VYVGART HYTRULO, are approved in the United States, Europe, and Japan. On May 9, Douglas Tsao, an analyst at H.C. Wainwright, reiterated a Buy rating on the stock with a price target of $720. The analyst noted the company grew net product sales for VYVGART, which exceeded market expectations. The company reported its fiscal first quarter results for 2025 on May 8. Management noted that it generated a total operating income of $807 million, driven primarily by $790 million in product net sales, which represents a 99% increase compared to the same quarter in the previous year. The product sales of argenx SE (NASDAQ:ARGX) were geographically diversified, with the majority of sales coming from the US. The analyst, Tsao, noted that the upcoming launch of Vyvgart's prefilled syringe (PFS), expected to improve patient accessibility and convenience. Management of the company also expects that the self-injection is expected to further expand patient access by enabling easier self-administration and reaching new patient populations. argenx SE (NASDAQ:ARGX) ranks as one of the best growth stocks to buy and hold for the long term. Artisan Small Cap Fund stated the following regarding argenx SE (NASDAQ:ARGX) in its Q4 2024 investor letter: 'We ended our investment campaigns in argenx SE (NASDAQ:ARGX), Tyler Technologies and Interparfums. Shares of Argenx have continued their year-to-date ascent due to multiple positive developments, including FDA approval to promote VYVGART® for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and strong sales execution of VYVGART®'s first approved indication in myasthenia gravis. While we continue to have high conviction, the company has outgrown our small-cap mandate, and we exited our position after a successful multiyear investment campaign.' Overall ARGX ranks 9th on our list of the best growth stocks to buy and hold for the long term. While we acknowledge the potential of ARGX as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than ARGX but that trades at less than 5 times its earnings, check out our report about this . READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
14-05-2025
- Business
- Yahoo
argenx SE (ARGX): Among the Best Growth Stocks to Buy and Hold for the Long Term
We recently compiled a list of the . In this article, we are going to take a look at where argenx SE (NASDAQ:ARGX) stands against the other growth stocks. The market closed last week mostly lower, however, the S&P 500 has been up more than 7% since April 11, indicating a returning positive sentiment. On May 10, David Lefkowitz, Equity Strategist at UBS Global Wealth Management, joined CNBC to discuss his bull case for the US equities. Lefkowitz acknowledged the volatility that has been around since the tariff announcement; however, he believes that backdrop remains fairly constructive. He elaborated that the market has had some significant buy signals since early April, characterised by the volatility index giving one of the highest readings, investor sentiment being cautious, and investor positioning has been depressed. Historically speaking, whenever these things have happened in the past, the US equities have performed exceptionally well in the preceding 6 to 12 months. Lefkowitz noted that he is not too concerned with the day-to-day news and volatility, as the market will get choppy on trade negotiation deals. Rather, he is more focused on the bigger picture, which indicates that stocks will ultimately end up higher over the next 12 months. While answering a question regarding the recent rebound in the market, Lefkowitz highlighted that when the volatility index comes down, as it has over the past few weeks, history tells us that the market does not make new lows. Although the market will still be chopping a little. However, it is anticipated to stay within the historic average of 5%. Moreover, the equity strategist is also not concerned about the valuations and believes that as soon as the companies start posting earnings growth, the backdrop will help the market reach its next high. While talking about his most convicted sectors, Lefkowitz noted that he likes secular growth stocks. He elaborated that growth as a sector was hit earlier this year due to doubts regarding AI trends and its ability to generate a return on investment. This has resulted in the sector being at the bottom of the market. However, Lefkowitz believes that the demand for AI products and the sophisticated infrastructure will keep growing for at least the next few years, thereby generating sustainable earnings growth. To compile the list of 12 best growth stocks to buy and hold for the long term, we used the Finviz stock screener, Seeking Alpha, and Insider Monkey's Q4 2024 hedge fund database. Using the screener, we aggregated a list of growth stocks that have grown their sales by at least 30% over the past 5 years. Next, we cross-checked the 5-year sales growth for each stock from Seeking Alpha and ranked the stocks in ascending order of the number of hedge fund investors. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (). A lab setting filled with scientific equipment and researchers in lab coats working together to develop new therapies for autoimmune diseases. argenx SE (NASDAQ:ARGX) is a commercial-stage biotechnology company that focuses on developing antibody therapeutics for autoimmune diseases and cancer. It uses its proprietary discovery platform to leverage unique characteristics of the llama immune system and engineer antibody medicines. Its lead products, VYVGART and VYVGART HYTRULO, are approved in the United States, Europe, and Japan. On May 9, Douglas Tsao, an analyst at H.C. Wainwright, reiterated a Buy rating on the stock with a price target of $720. The analyst noted the company grew net product sales for VYVGART, which exceeded market expectations. The company reported its fiscal first quarter results for 2025 on May 8. Management noted that it generated a total operating income of $807 million, driven primarily by $790 million in product net sales, which represents a 99% increase compared to the same quarter in the previous year. The product sales of argenx SE (NASDAQ:ARGX) were geographically diversified, with the majority of sales coming from the US. The analyst, Tsao, noted that the upcoming launch of Vyvgart's prefilled syringe (PFS), expected to improve patient accessibility and convenience. Management of the company also expects that the self-injection is expected to further expand patient access by enabling easier self-administration and reaching new patient populations. argenx SE (NASDAQ:ARGX) ranks as one of the best growth stocks to buy and hold for the long term. Artisan Small Cap Fund stated the following regarding argenx SE (NASDAQ:ARGX) in its Q4 2024 investor letter: 'We ended our investment campaigns in argenx SE (NASDAQ:ARGX), Tyler Technologies and Interparfums. Shares of Argenx have continued their year-to-date ascent due to multiple positive developments, including FDA approval to promote VYVGART® for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and strong sales execution of VYVGART®'s first approved indication in myasthenia gravis. While we continue to have high conviction, the company has outgrown our small-cap mandate, and we exited our position after a successful multiyear investment campaign.' Overall ARGX ranks 9th on our list of the best growth stocks to buy and hold for the long term. While we acknowledge the potential of ARGX as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than ARGX but that trades at less than 5 times its earnings, check out our report about this . READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
09-05-2025
- Business
- Yahoo
argenx SE (ARGX): Among the Best Cancer Stocks to Invest in for Long-Term Gain
We recently published a list of . In this article, we are going to take a look at where argenx SE (NASDAQ:ARGX) stands against other best cancer stocks to invest in for long-term gain. After cardiovascular disease, cancer is the second most common cause of mortality worldwide. In January 2023, the American Cancer Society released figures indicating that by the end of 2023 alone, there would be approximately 1,958,310 cancer patients in the United States. Compared to 2010, this is a 28% increase. In the United States, it was anticipated that over 600,000 people would die from cancer in 2024, and over 2 million new cases would be diagnosed. Cancer treatment expenses are rising in tandem with the growing number of cancer sufferers. In 2020, cancer treatment in the United States cost about $200 billion, but by 2030, the total cost is expected to surpass $245 billion. Over the past 20 years, global funding for cancer research has increased dramatically, according to the 'Oncology Pharmaceuticals Market 2024' report. Between 2017 and 2022, the FDA authorized 161 new cancer medicines, demonstrating the rapid advancement of cancer treatment. According to these figures, oncology is among the most extensive fields within the field of biological sciences. From diagnosis to therapy, the whole cancer care process is covered by the oncology industry. Global biotech and pharmaceutical businesses are always working to create more potent cancer treatments. Fortune Business Insights predicts that the scope of this undertaking will only grow shortly. In 2023, the global market for cancer medications was estimated to be worth $201.75 billion. It is projected to increase from $220.80 billion in 2024 to $518.25 billion by 2032 at a compound annual growth rate (CAGR) of 11.3%. The development of tailored immunotherapies for cancer treatment and the rising incidence of cancer worldwide are some of the main reasons propelling the market for oncology medications. Investing in businesses related to oncology is a profitable venture due to this growth rate. The global market for oncology medications is dominated by North America. In 2023, its market share was 45.92%. The market for precision oncology exhibits comparable patterns. Precision oncology, according to the National Institutes of Health (NIH), is a type of treatment in which doctors select therapies while taking into account each patient's unique tumor's DNA signature. In 2024, the global precision oncology market was estimated to be worth $115.8 billion, according to data from Grand View Research. A compound annual growth rate (CAGR) of 8.05% is projected between 2025 and 2030. The rising need for diagnostic products, technical advancements, avoiding specific medication resistance, and the growing reduction of adverse effects of cancer treatments are all factors contributing to this growth. AI usage is rapidly growing in the field of cancer. A study by Mordor Intelligence projects that the size of the AI in the cancer industry will be approximately $1.98 billion in 2025 and will grow to approximately $9.04 billion by 2030. This represents growth from 2025 to 2030 at a CAGR of 35.51%. AI's growing use in the diagnosis, analysis, and treatment of complicated oncology datasets is simplifying the process and lessening the strain on medical staff and hospital infrastructure. Although North America is the largest market for AI in oncology, the Asia-Pacific area is the one with the quickest rate of growth. Given this, we will take a look at some of the best cancer stocks for long term gains. In our methodology, we first filtered cancer stocks based on their 5-year average returns. From this pool, we identified the top 10 stocks with the highest number of hedge fund holders as of Q4 2024, according to the Insider Monkey database. In cases where multiple stocks had the same number of hedge fund holders, we used their 5-year total returns as a tiebreaker, ranking the stock with the higher return above the others. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here). A lab setting filled with scientific equipment and researchers in lab coats working together to develop new therapies for autoimmune diseases. Number of Hedge Fund Holders: 47 Total 5-Year Return: 333.46% argenx SE (NASDAQ:ARGX) is a global biopharma company specializing in antibody-based therapies for autoimmune diseases and cancer. Its proprietary SIMPLE Antibody platform enables the development of highly effective, differentiated antibodies. The company's lead product, VYVGART, is an FcRn antagonist and targets the neonatal Fc receptor to reduce harmful antibodies and is approved for conditions like myasthenia gravis and CIDP. argenx SE (NASDAQ:ARGX) reported $737 million in product net sales for the fourth quarter of 2024 and $2.2 billion for the entire year. Its net profit was $774 million in Q4 and $833 million in 2024, while total operating income was $761 million in Q4 and $2.3 billion for the year. The business had a healthy $3.4 billion cash position after the year. A 98% year-over-year increase in product net sales allowed argenx SE (NASDAQ:ARGX) to reach over 10,000 patients worldwide across three approved indications. VYVGART, its flagship medication, is being widely used in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) and has significantly impacted the therapy of generalized myasthenia gravis (gMG). With ambitious targets for the future, the corporation is moving forward with its Vision 2030 strategy: treating 50,000 patients, obtaining 10 labeled indications, and advancing five pipeline prospects to Phase 3. With 20 ongoing clinical trials, including 10 Phase 3 and 10 Phase 2 investigations, the company is well-positioned for long-term success. With anticipated R&D and SG&A expenditures of $2.5 billion, argenx SE (NASDAQ:ARGX) anticipates 2025 to be its first profitable year, demonstrating its dedication to innovation. With a favorable CHMP recommendation for the VYVGART pre-filled syringe in the EU and an FDA decision anticipated by April 10, 2025, the regulatory process is still ongoing and might increase treatment accessibility and market reach. Overall, ARGX ranks 3rd on our list of best cancer stocks to invest in for long-term gain. While we acknowledge the potential of cancer companies, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than ARGX but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
08-05-2025
- Business
- Yahoo
Is argenx SE (ARGX) the Most Profitable Growth Stock to Buy Now?
We recently published a list of . In this article, we are going to take a look at where argenx SE (NASDAQ:ARGX) stands against other most profitable growth stocks to buy now. The growth factor in investing refers to companies that grow their revenue and earnings at rates significantly above the market. These companies are usually small and young, operate in high-growth and less mature industries, and often lack the financial stability and resilience of their more mature counterparts. As a result, the growth factor becomes highly attractive and outperforms during secular bull markets (such as the 2010-2021 period) dominated by macroeconomic stability and low interest rates. On the other hand, the return of growth stocks significantly lags behind during bear markets or periods of heightened uncertainty and volatility. For reference, the growth factor underperformed significantly during the 2022 bear market as well as the 2025 year-to-date. While the growth strategy delivers superior returns most of the time, we believe there are ways to refine it and make it more reliable. One of the weaknesses of most growth stocks is weak profitability (due to aggressive investments in working capital for growth or R&D), which makes them more susceptible to economic downturns. The solution to this is to incorporate a profitability criterion as well – growth stocks with strong profitability will navigate economic slowdowns better and hold up well even during recessions. Our hypothesis is confirmed by modern financial research; the Fama-French 5-Factor Model (2015) introduced a profitability factor which, as the authors claim, can explain stock returns – stocks of companies with high profitability tend to outperform those with low profitability. READ ALSO: As legendary Warren Buffett has advised, to be greedy when others are fearful, we believe the best way to make money in the market is to engage in smart contrarian bets when everyone else is reluctant. The US stock market is still more than 10% below its all-time high as market participants are still digesting the tariffs situation as well as the new economic data, which is quite disappointing. The Philadelphia Fed manufacturing index decreased to -26.4 in April, well below expectations and the lowest reading since April 2023. It is also the second lowest level outside of official recessions, which hints towards the possibility that we are already in a recession that will only be declared at a later date. The employment, shipments, and new orders components all decreased as well, further pointing towards a slowing economy. Business surveys have also been quite grim – Hamilton Lane recently reported that at least 62% of CEOs see a recession on the horizon, while the 6-month Capex expectations fell to the lowest level since the pandemic. It is now clear that pretty much everyone is thinking about a recession now, and that's actually the most bullish indicator out there. The stock market is a forward-looking animal, meaning that its prices reflect the state of the economy 6-12 months from now. Given that the average recession in the US has historically lasted for about 3-4 quarters, and assuming that revised Q1 2025 data will be later recognized as the beginning of the recession, odds are that the US economy will already return to growth in calendar 2026. Also, history shows that the forward-looking stock market tends to disappoint the majority of investors, which means that if the majority expects a recession, then odds are that it is already priced in and that the market bottom is already in the rear-view mirror. To sum up, the fact that the US economy is in a slowdown and a state of uncertainty is pretty much obvious at this point. The key takeaway for readers is that stock prices are forward-looking and reflect the investors' outlook for several quarters ahead. Once it becomes completely clear that calendar 2026 will be past the current tariff turmoil, the US stock market will very likely return to growth. It is therefore an opportune moment to look for the most profitable growth stocks to add in anticipation of a broad market melt-up. A lab setting filled with scientific equipment and researchers in lab coats working together to develop new therapies for autoimmune diseases. To compile our list of most profitable growth stocks, we used a screener to identify stocks with at least 30% revenue CAGR in the last 5 years and a net profit margin of at least 20%. Then we included in the article the top 13 stocks with the highest net profit generated in the most recent fiscal year, ranked in ascending order. We also included the number of hedge funds that own each stock, as per Insider Monkey's Q4 2024 database. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points ().argenx SE (NASDAQ:ARGX) is a biotechnology company based in the Netherlands that specializes in antibody-based therapies for severe autoimmune diseases. Its lead product is marketed as VYVGART and is approved in multiple countries for treating generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. The company's growth story relies on the successful advancement of a pipeline of therapies targeting various autoimmune conditions. The year 2024 was successful for argenx SE (NASDAQ:ARGX), with the company expanding its reach to over 10,000 patients globally across 3 approved indications. The company achieved several clinical milestones, including 'empasiprubart' advancing to Phase III, following impressive preclinical data, and successfully moving 'efgartigimod' into larger registrational studies in Sjogren's disease and 3 subsets of myositis. The company's commercial success was evident with product net sales reaching $737 million for Q4 and $2.2 billion for the full year, representing 29% QoQ growth and 98% growth YoY. Looking ahead to 2025, argenx SE (NASDAQ:ARGX) will mark its first year as a profitable company, reflecting its commercial success and disciplined execution. The company is advancing an ambitious clinical program with 10 Phase III studies and 10 proof-of-concept studies across 'efgartigimod', 'empasiprubart,' and ARGX-119. The anticipated launch of the prefilled syringe, which opens the door for self-administration in the US, is expected to be a key growth driver in 2025. ARGX maintains a strong financial position with a cash balance of $3.4 billion at year-end, further reinforcing its position as one of the most profitable stocks on our list. Overall, ARGX ranks 13th on our list of most profitable blue chip stocks to buy now. While we acknowledge the potential of ARGX as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than ARGX but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
07-05-2025
- Business
- Yahoo
argenx SE (ARGX): A Bull Case Theory
We came across a bullish thesis on argenx SE (ARGX) on Substack by FluentInQuality. In this article, we will summarize the bulls' thesis on ARGX. argenx SE (ARGX)'s share was trading at $629.51 as of April 29th. ARGX's trailing and forward P/E were 49.26 and 90.91 respectively according to Yahoo Finance. Is Alzamend Neuro, Inc. (ALZN) the Cheapest Stock Insiders Are Buying In March? A biopharmaceutical facility with technicians working on a manufacturing line of treatments and preventions. argenx SE (ARGX) is emerging as a transformative force in the autoimmune space, not as a traditional biotech chasing one-off blockbuster drugs, but as a platform company methodically scaling a repeatable, high-leverage model. Its core strength lies in a single mechanism—FcRn inhibition—which is being deployed across a range of autoimmune conditions. The flagship therapy, Vyvgart, a first-in-class FcRn blocker, has already been approved for generalized myasthenia gravis (gMG), with promising expansion into chronic inflammatory demyelinating polyneuropathy (CIDP) and trials underway in autoimmune hematology, dermatology, and nephrology. This strategic expansion isn't random—it reflects a deliberate, pipeline-as-platform approach where each successful indication unlocks adjacent markets, accelerating scale and reach. What makes argenx particularly compelling is the chronic nature of the diseases it targets. Autoimmune conditions don't resolve; they require long-term management, translating into durable, recurring revenue. Vyvgart has already crossed €1 billion in annualized revenue, aided by the introduction of a subcutaneous formulation that enhances ease of access and adherence. As global rollout efforts continue across Europe, Japan, and China, and new indications come online, the addressable market keeps expanding. This isn't one-time therapy revenue—it's foundational, high-margin income in largely underserved, fragmented markets. Beyond Vyvgart, argenx is leveraging its FcRn-focused antibody platform to build a deep pipeline, including multiple efgartigimod variants targeting new autoimmune indications, with preclinical efforts also branching into oncology and nephrology. This diversification, grounded in a single, validated biological mechanism, reduces risk with each subsequent success. It's a textbook example of platform biotech, where discovery scale and efficiency create significant long-term optionality—far beyond the narrow view of being a 'single-asset' or 'rare disease' player. Financially, while current R&D investments remain substantial, they are the fuel driving platform expansion. As revenues scale, manufacturing efficiencies and global reach are set to unlock meaningful operating leverage. Argenx is now transitioning from the heavy investment phase to one where margins are expected to expand materially.
